Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EP300 | Q09472 | 2/20 | 0.50 |
| ▸ | DUT | P33316 | 3/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667245 | 0.83 | ALDH1A1 (0.59) | L3MBTL1PKMALDH1A1LMNAKMT2A | |
| SCHEMBL27703786 | 0.80 | ALDH1A1 (0.55) | L3MBTL1PKMALDH1A1LMNAKMT2A | |
| SCHEMBL11983580 | 0.80 | ALDH1A1 (0.58) | L3MBTL1PKMALDH1A1LMNAKMT2A | |
| SCHEMBL19370603 | 0.79 | ALDH1A1 (0.51) | L3MBTL1PKMALDH1A1LMNAKMT2A | |
| SCHEMBL6280756 | 0.79 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1LMNAKMT2ADUT | |
| SCHEMBL3589734 | 0.79 | KMT2A (0.50) | ALDH1A1LMNAKMT2AGSK3AGSK3B | |
| SCHEMBL2899640 | 0.78 | ALDH1A1 (0.59) | L3MBTL1PKMALDH1A1LMNAKMT2A | |
| SCHEMBL11710759 | 0.76 | ALDH1A1 (0.58) | L3MBTL1PKMALDH1A1LMNAKMT2A | |
| SCHEMBL11710750 | 0.76 | ALDH1A1 (0.58) | L3MBTL1PKMALDH1A1LMNAKMT2A | |
| SCHEMBL28198563 | 0.76 | PKM (0.58) | PKMALDH1A1LMNAKMT2AEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11578090-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200385414-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| WO-2020247782-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-1290169-A2 | CYSTINE-KNOT POLYPEPTIDES: CLOAKED-2 MOLECULES AND USES THEREOF | Amgen, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-0718290-B1 | Carboxyalkyl heterocyclic derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001092308-A2 | CYSTINE-KNOT POLYPEPTIDES: CLOAKED-2 MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-5912261-A | ANTIDIABETIC AGENTS | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-15 | — | — | US | disclosed |
| EP-0718290-A1 | Carboxyalkyl heterocyclic derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385414-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | L3MBTL1 1023/4885PKM 2135/4885ALDH1A1 4367/4885 |
| US-11578090-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | L3MBTL1 1023/4885PKM 2135/4885ALDH1A1 4367/4885 |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | L3MBTL1 1023/4885PKM 2135/4885ALDH1A1 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.